The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
=== Electrophysiology === Electroencephalography (EEG) is not routinely used as a primary test for Alzheimer's disease but may assist in the differential diagnosis of cognitive impairment by helping exclude metabolic encephalopathies, Creutzfeldt–Jakob disease, epileptic disorders, and some atypical dementias. EFNS Quantitative EEG studies consistently demonstrate slowing of the dominant posterior rhythm, increased theta and delta activity, reduced alpha power, and disrupted functional connectivity, changes that correlate with disease severity and cognitive decline. Expert consensus considers resting-state EEG a promising non-invasive test for research, patient stratification, and monitoring in clinical trials, although it is not recommended as a substitute for established imaging or fluid biomarkers. Event-related potentials (ERPs), particularly the P300 component, have also been extensively investigated. Meta-analyses show significantly reduced P300 amplitude in patients with Alzheimer's disease, while prolonged latency has been reported in many studies, reflecting impaired cognitive processing. Despite these findings, variability between recording protocols has limited the routine clinical use of ERP measures, and they remain primarily research tools.
Unstable angina is a type of angina pectoris that is irregular or more easily provoked. It is classified as a type of acute coronary syndrome. It can be difficult to distinguish unstable angina from non-ST elevation (non-Q wave) myocardial infarction. They differ primarily in whether the ischemia is severe enough to cause sufficient damage to the heart's muscular cells to release detectable quantities of a marker of injury, typically troponin T or troponin I. Unstable angina is considered to be present in patients with ischemic symptoms suggestive of an acute coronary syndrome and no change in troponin levels, with or without changes indicative of ischemia (e.g., ST segment depression or transient elevation or new T wave inversion) on electrocardiograms.
Daily salivation of vampire bats yields a saliva that progressively decreases in anticoagulant activity. However, there is no significant change in overall protein content during this time. After a 4-day period of rest, anticoagulant activity of the saliva is restored. In addition, purified native Draculin, obtained from high- and low-activity saliva, shows significant differences in composition of the carbohydrate moiety, and glycosylation pattern. Furthermore, controlled chemical de-glycosylation of native Draculin progressively leads to complete loss of the biological activity, despite the conditions leaving the polypeptide backbone intact. These results suggest that oligosaccharides linked to Draculin are essential for it to express against FXa. In addition, it suggests that Draculin is actually secreted as a mixture of glycoforms. The final anticoagulant activity of Draculin then, in turn, relies on correct glycosylation, implying that glycosylation is the limiting step for production of Draculin with optimal anticoagulant properties. In this regard, the appropriate glycosylation of Draculin may be in part responsible for the dual, independent, inhibitory action of native Draculin on FIXa and FXa, suggesting a novel mechanism of inhibition which is different from other known natural inhibitors of FXa.
state of matter The condition of matter existing in a distinct, homogeneous, macroscopic form. Solid, liquid, gas, and plasma are the four traditional states of matter and the most well-known. See also phase.
== External links == ENZYME — Expasy enzyme nomenclature database ENZO — Web application for easy construction and quick testing of kinetic models of enzyme catalyzed reactions. ExCatDB — A database of enzyme catalytic mechanisms BRENDA — Comprehensive enzyme database, giving substrates, inhibitors and reaction diagrams
Sources: en.wikipedia.org
=== Further manifestations of periodicity === There are some other relationships throughout the periodic table between elements that are not in the same group, such as the diagonal relationships between elements that are diagonally adjacent (e.g. lithium and magnesium). Some similarities can also be found between the main groups and the transition metal groups, or between the early actinides and early transition metals, when the elements have the same number of valence electrons. Thus uranium somewhat resembles chromium and tungsten in group 6, as all three have six valence electrons. Relationships between elements with the same number of valence electrons but different types of valence orbital have been called secondary or isodonor relationships: they usually have the same maximum oxidation states, but not the same minimum oxidation states. For example, chlorine and manganese both have +7 as their maximum oxidation state (e.g. Cl2O7 and Mn2O7), but their respective minimum oxidation states are −1 (e.g. HCl) and −3 (K3[Mn(CO)4]). Elements with the same number of valence vacancies but different numbers of valence electrons are related by a tertiary or isoacceptor relationship: they usually have similar minimum but not maximum oxidation states. For example, hydrogen and chlorine both have −1 as their minimum oxidation state (in hydrides and chlorides), but hydrogen's maximum oxidation state is +1 (e.g. H2O) while chlorine's is +7.
Mummies from various dynasties throughout China's history have been discovered in several locations across the country. They are almost exclusively considered to be unintentional mummifications. Many areas in which mummies have been uncovered are difficult for preservation, due to their warm, moist climates. This makes the recovery of mummies a challenge, as exposure to the outside world can cause the bodies to decay in a matter of hours. An example of a Chinese mummy that was preserved despite being buried in an environment not conducive to mummification is Xin Zhui. Also known as Lady Dai, she was discovered in the early 1970s at the Mawangdui archaeological site in Changsha. She was the wife of the Marquis of Dai during the Han dynasty, who was also buried with her alongside another young man often considered to be a very close relative. However, Xin Zhui's body was the only one of the three to be mummified. Her corpse was so well-preserved that surgeons from the Hunan Provincial Medical Institute were able to perform an autopsy. The exact reason why her body was so completely preserved has yet to be determined. Among the mummies discovered in China are those termed Tarim mummies because of their discovery in the Tarim Basin. The dry desert climate of the basin proved to be an excellent agent for desiccation. For this reason, over 200 Tarim mummies, which are over 4,000 years old, were excavated from a cemetery in the present-day Xinjiang region. The mummies were found buried in upside-down boats with hundreds of 13-foot-long wooden poles in the place of tombstones.
==== Police reform ==== Newsom has spoken in favor of Assembly Bill 1196, which would ban carotid artery restraints and choke holds in California. He said that there is no longer a place for a policing tactic "that literally is designed to stop people's blood from flowing into their brain, that has no place any longer in 21st-century practices". Newsom has signed the California Act to Save Lives and California Racial Justice Act of 2020. In September 2021, he signed legislation raising the minimum age to become a police officer from 18 to 21. Also in the bills were restrictions on the use of tear gas and a ban on police departments employing officers after misconduct or crimes. Among the bills was the George Floyd Bill, requiring officers to intervene when witnessing excessive force on the part of another officer. Newsom vetoed Assembly Bill 2681 which sought to restrict autonomous weapons citing "beneficial law enforcement use of such devices". Newsom vetoed Assembly Bill 2632, which sought to limit solitary confinement. In October 2024, Newsom vetoed Assembly Bill 2693, which sought to extend the statute of limitations for those sexually abused in juvenille facilities. In 2025, Newsom vetoed Senate Bill 274, which would have expanded the rules and regulations on law enforcement agencies, in California, use of automated license plate readers. In his veto message, he stated the proposed regulations, which would have required police to better document their searches and delete unused data within 60 days, could hinder police work.
=== Protein degradation === Protein degradation may take place intracellularly or extracellularly. In digestion of food, digestive enzymes may be released into the environment for extracellular digestion whereby proteolytic cleavage breaks proteins into smaller peptides and amino acids so that they may be absorbed and used. In animals the food may be processed extracellularly in specialized organs or guts, but in many bacteria the food may be internalized via phagocytosis. Microbial degradation of protein in the environment can be regulated by nutrient availability. For example, limitation for major elements in proteins (carbon, nitrogen, and sulfur) induces proteolytic activity in the fungus Neurospora crassa as well as in of soil organism communities. Proteins in cells are broken into amino acids. This intracellular degradation of protein serves multiple functions: It removes damaged and abnormal proteins and prevents their accumulation. It also serves to regulate cellular processes by removing enzymes and regulatory proteins that are no longer needed. The amino acids may then be reused for protein synthesis.
Although the mechanism of this reaction has not been fully elucidated, it is speculated that the use of an electron-deficient phosphonate accelerates elimination of the oxaphosphatane intermediate. This renders the initial addition of the phosphonate-stabilized carbanion to the aldehyde effectively irreversible, leading to Z-selectivity in analogy to the standard Wittig reaction.
Sources: en.wikipedia.org
For services to the Bangladeshi Community and to Charity. Elinor Muriel Middlemiss. Chef de Mission, Scotland Commonwealth Games Team. For services to Sport. Christopher Neill Middleton. Operational Delivery Deputy Director, Home Office. For Public and Voluntary Service. Steven Richard Miller. Director of Culture and Heritage, Head of Norfolk Museums Service, Norfolk County Council. For services to Heritage and Tourism. Louisa Jane Mitchell. Chief Executive, West London Zone (WLZ). For services to Children and Young People. Stephen Moffitt. Chief Executive Officer, A New Direction. For services to the Arts and Culture. Alison Jane Moffitt-Robinson. For services to Sports Management and Development in Northern Ireland. Huda Mohamed Yassin. Female Genital Mutilation Specialist Lead Midwife, Whittington Health NHS Trust. For services to Midwifery. Kathryn Ann Morley. Lately Chief Executive Officer, OnSide. For services to Young People. Fiona Bennett Morrison. Lately Community Fund Manager, Scottish and Southern Electricity Renewables. For services to the community in the Scottish Highlands. Doreen Lilian Mortimer. Volunteer Shop Manager, Tenby Lifeboat Station, Royal National Lifeboat Institution. For Voluntary Services. Andrew Bernard Moseley. Service Leader, Department for Work and Pensions. For public service in South East Wales. Peter Mountford. Lately Executive Chairman, Heropreneurs. For voluntary services to Armed Forces Personnel. Denise Murdoch. Senior Operations Manager, Carr Gomm. For services to Older People in Argyll and Bute. Alison Margaret Murray.
==== Quantitative real-time polymerase chain reaction (qRT-PCR) ==== A more sensitive approach to transcript analysis of a gene is quantitative real-time polymerase chain reaction (qRT-PCR), which has also seen action in quantifying protease mRNA levels. Again, total RNA is extracted and used to generate cDNA for PCR amplification. As long as there is a specific primer for a protease, protease inhibitor, or interacting molecule, qRT-PCR can serve as a highly sensitive method to detect minuscule amounts of mRNA copy numbers per cell. A drawback that separates it from microarray analysis is its limited scope: a microarray can handle parallel analysis of multiple genes while qRT-PCR must amplify one mRNA for analysis at a time. It also suffers from the same limitation of microarray analysis regarding the lack of correlation between transcript and protein levels. However, its sensitivity lends it as a useful tool in validating microarray findings and quantifying specific protease transcripts of interest.
Ordinarily, new scientific discoveries are claimed to be consistent and reproducible; as a result, if the experiments are not complicated, the discovery can usually be confirmed or disproved in a few months. The claims of cold fusion, however, are unusual in that even the strongest proponents of cold fusion assert that the experiments, for unknown reasons, are not consistent and reproducible at the present time. (...) Internal inconsistencies and lack of predictability and reproducibility remain serious concerns. (...) The Panel recommends that the cold fusion research efforts in the area of heat production focus primarily on confirming or disproving reports of excess heat.
Titanic transformed DiCaprio into a superstar, drawing adoration among teenage girls and young women that became known as "Leo-mania". The success bolstered DiCaprio's standing as a teen idol and romantic lead, an image from which he sought to dissociate himself. Despite the film's success and its positive influence on his career, in 2025 DiCaprio said he regretted the decision to turn down Boogie Nights, saying it was "a profound movie of my generation". In his 2015 Rolling Stone article, Ebiri called the Titanic role DiCaprio's best, writing that he and Winslet "infuse their earnest back-and-forth with so much genuine emotion that it's hard not to get swept up in their doomed love affair". A writer for Vanity Fair in 2008 labeled them "Hollywood's most iconic screen couple" since Humphrey Bogart and Ingrid Bergman. Writing about her first viewing of Titanic in 2017, Vox contributor Alissa Wilkinson described DiCaprio's "boyish charm" and found his performance "natural and unaffected". DiCaprio had a brief featured role in Woody Allen's 1998 satire of fame, Celebrity. Ebiri labeled DiCaprio "the best thing in the film". That year, he also took on the dual roles of villainous King Louis XIV and his secret, sympathetic twin brother Philippe in Randall Wallace's The Man in the Iron Mask, with common elements from the 1939 film and a 1929 film with Douglas Fairbanks. It received mixed reviews, but grossed $180 million against a budget of $35 million.
Phalen's maneuver. Performed by fully flexing the wrist, then holding this position and awaiting symptoms. A positive test results in paresthesia in the median nerve distribution within sixty seconds. Tinel's sign is performed by lightly tapping the median nerve just proximal to flexor retinaculum to elicit paresthesia. Durkan's test, carpal compression test, or applying firm pressure to the palm over the nerve for up to 30 seconds to elicit paresthesia. The hand elevation test, performed by lifting both hands above the head. Paresthesia in the median nerve distribution within 2 minutes is considered positive. Diminished threshold sensibility (the ability to distinguish different amounts of pressure) can be measured using Semmes-Weinstein monofilament testing. This test establishes impaired or loss of sensation. Electrodiagnostic testing including electromyography, and nerve conduction studies can objectively measure and verify median neuropathy. Ultrasound can image and measure the cross-sectional diameter of the median nerve, which has some correlation with CTS. The role of ultrasound in diagnosis—just as with electrodiagnostic testing—is a matter of debate. Data suggests that electrodiagnostic testing cannot detect the presence of CTS in 16% to 34% of people who have the condition. The role of confirmatory electrodiagnostic testing is controversial. The goal of electrodiagnostic testing is to compare the speed of conduction in the median nerve with conduction in other nerves supplying the hand.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.